On Wednesday, Guess?, Inc. (NYSE:GES)’s shares inclined 2.18% to $20.13.
Lululemon presently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same industry comprise G-III Apparel Group, Ltd. GIII and Guess?, Inc. (GES).
Lululemon Athletica Inc. LULU stated solid first-quarter fiscal 2015 results despite the challenges posed by currency headwinds, unfavorable weather and port delays. The company’s top and bottom line results exceeded its own expectations, thereby encouraging administration to raise its fiscal 2015 outlook.
Quarterly earnings of 34 cents per share were in line with the Zacks Consensus Estimate in addition to the year-ago figure. However, earnings came ahead of the company’s forecast of a range of 31–33 cents per share.
Backed by improved total comparable sales (comps) and addition of new stores, Lululemon’s quarterly revenues advanced 10.1% to $423.5 million, surpassing the Zacks Consensus Estimate of $417.8 million in addition to the company’s projection of a range of $413–$418 million.
Total comps grew 6% on a constant dollar basis, driven by a 31% surge in Direct-to-Consumer sales, partly offset by a 1% dip in quarterly comps.
Guess?, Inc. designs, markets, distributes, and licenses lifestyle collections of contemporary apparel and accessories for men, women, and children that reflect the American lifestyle and European fashion sensibilities. It operates through North American Retail, Europe, Asia, North American Wholesale, and c segments.
Glu Mobile Inc. (NASDAQ:GLUU)’s shares gained 0.15% to $6.54.
Glu Mobile Inc. (GLUU) At the Annual Meeting, Glu’s stockholders (1) elected three persons as Class II directors to Glu’s Board of Directors, each to serve until Glu’s annual meeting of stockholders to be held in 2018 and until his or her successor is elected and qualified, or until his or her death, resignation or removal; (2) approved the amendment and restatement of Glu’s 2007 Equity Incentive Plan; and (3) ratified the appointment of PricewaterhouseCoopers LLP as Glu’s independent registered public accounting firm for the fiscal year ending December 31, 2015. The proposals are described in Glu’s proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 21, 2015, as supplemented by a Form 8-K filing on May 27, 2015.
Glu Mobile Inc. develops, publishes, and markets a portfolio of games for the smartphones and tablet devices users. The company offers free-to-play action, casual, racing, and sports genre mobile games.
At the end of Wednesday’s trade, American Capital Ltd. (NASDAQ:ACAS)‘s shares surged 0.14% to $14.00.
American Capital Ltd. (ACAS) declared that it acted as sole lender and second lien agent on a $51 million second lien financing to support the acquisition of Compusearch Software Systems, Inc. (“Compusearch”) by ABRY Partners. Compusearch is the leading provider of acquisition and program administration software to federal agencies, Department of Defense program offices and government contractors.
Headquartered in Dulles, VA, Compusearch provides software and services that advance commerce and partnership among government agencies and contractors. Compusearch’s PRISM™ software is fully compliant with Federal Acquisition Regulations and is the contract writing system for defense, intelligence and civilian agencies. PRISM™ automates requisition and solicitation generation, competitive bid evaluation, award generation, contract administration, administration reporting, and contract closeout and archiving, and also significantly speeds up compliance with the complex bidding rules for federal contracts. Compusearch’s software solutions also comprise TopVue™ for program execution and deliverable support and SpectrumCLM™ for Government Contractor’s Contract Lifecycle Administration (CLM) processes.
American Capital, Ltd. is a private equity and venture capital firm specializing in administration and employee buyouts, subordinated debt, leveraged finance, mezzanine, acquisition, recapitalization, middle market, early venture, mature, industry consolidation, and growth capital investments.
Biogen Inc (NASDAQ:BIIB), ended its Wednesday’s trading session with 1.70% gain, and closed at $388.50.
Biogen Inc (BIIB) and Samsung Bioepis Co., Ltd recently declared that results from their anti-TNF biosimilar portfolio are being presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, June 10–13, 2015. Highlights comprise results from separate head-to-head Phase III studies showing clinical comparability of SB4 (etanercept) and SB2 (infliximab), which are biosimilar development candidates to their respective reference products Enbrel®1 and Remicade®2. Also being presented are equivalence data from a Phase I pharmacokinetic (PK) study comparing SB5 (adalimumab), a biosimilar development candidate, with the reference product Humira®3. These results profile a promising anti-TNF biosimilar portfolio for the two companies.
SB2 data highlights
The 30-week data from a Phase III study comparing SB2 with the infliximab reference product Remicade, in patients with moderate to severe rheumatoid arthritis demonstrated SB2 to have an equivalent ACR20 response and a comparable safety profile.ii
- A total of 584 patients were randomized to either SB2 (N=291) or the infliximab reference product (N=293)ii
- The ACR20 response rate at week 30 in the PPS was 64.1% with SB2 and 66.0% with the infliximab reference group (adjusted difference -1.88%, 95% CI: -10.26%, 6.51%)ii
- The ACR20 from the FAS also showed equivalence of SB2 to the infliximab reference group, at 55.5% vs. 59.0%, respectively (adjusted difference -2.95%, 95% CI: -10.88%, 4.97%)ii
- SB2 was well tolerated with a comparable safety, PK, and immunogenicity to the infliximabreference productii
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
